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Circular RNAs (circRNAs) are broadly expressed in eukaryotic cells, but their molecular
mechanism in human disease remains obscure. Here we show that circular antisense
non-coding RNA in the INK4 locus (circANRIL), which is transcribed at a locus of atherosclerotic
cardiovascular disease on chromosome 9p21, confers atheroprotection by controlling ribo-
somal RNA (rRNA) maturation and modulating pathways of atherogenesis. CircANRIL binds
to pescadillo homologue 1 (PES1), an essential 60S-preribosomal assembly factor, thereby
impairing exonuclease-mediated pre-rRNA processing and ribosome biogenesis in vascular
smooth muscle cells and macrophages. As a consequence, circANRIL induces nucleolar stress
and p53 activation, resulting in the induction of apoptosis and inhibition of proliferation, which
are key cell functions in atherosclerosis. Collectively, these findings identify circANRIL as a
prototype of a circRNA regulating ribosome biogenesis and conferring atheroprotection,
thereby showing that circularization of long non-coding RNAs may alter RNA function and
protect from human disease.
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D
eep sequencing combined with novel bioinformatics
approaches led to the discovery that a significant portion
of the human transcriptome is spliced into RNA loops1–3.
These circular RNAs (circRNAs) do not retain the exon order
defined by their genomic sequence and are thought to originate
from non-canonical splicing of a 50 splice site to an upstream
30 splice site4. Recent studies suggest that exon circularization
may depend, in part, on inverted repeats or flanking intronic
complementary sequences5,6 but little is known about the
functions of these highly stable RNA forms.
Before the finding that circRNAs are abundantly transcribed in
humans, there were few reports of circRNAs in mammals. One of
the earliest examples is the sex determining region of Chr Y (Sry)
gene in mice, the Y chromosome encoded master regulator of the
testis-determining pathway7. Srymay be expressed as circular and
linear transcripts and circularization is thought to be a mecha-
nism to escape translation7,8. Sry was also shown to serve as a
competing endogenous RNA of miRNA-138 (ref. 9), and a similar
‘miRNA sponging’ function has been demonstrated for a
transcript antisense to cerebellar degeneration related protein 1
(CDR1as/ciRS-7)2,9. CDR1as contains B70 binding sites for
miR-7 and acts to suppress miR-7 activity, resulting in increased
levels of miR-7 target genes and functions2,9. However, only few
circRNAs harbour multiple binding sites for miRNAs10,
suggesting that these abundant RNAs may have other unknown
regulatory functions.
Previous work indicated that the long non-coding RNA
(lncRNA) ANRIL(CDKN2B-AS1), which is transcribed at
the cardiovascular disease risk locus on chromosome 9p21
(refs 11–13), is capable of forming RNA circles14, yet the
functional relevance in human health and disease is unknown.
ANRIL is differentially expressed by the genotype at 9p21
(for review see ref. 15) and increased linear ANRIL (linANRIL)
was associated with increased atherosclerosis16. Recent studies
suggest an important role for Alu elements in epigenetic gene
regulation by linANRIL17. These Alu repeats and distal ANRIL
exons are not conserved in non-primate species18, suggesting a
primate-specific gain of function of this lncRNA. Here we identify
a molecular effector mechanism of circular ANRIL (circANRIL)
using proteomic screening, bioinformatics and functional studies.
We demonstrate that circANRIL regulates the maturation of
precursor ribosomal RNA (pre-rRNA), thus controlling ribosome
biogenesis and nucleolar stress. In concert, circANRIL confers
disease protection by modulating apoptosis and proliferation in
human vascular cells and tissues, which are key cellular functions
in atherosclerosis.
Results
Association of circANRIL with atheroprotection at human
9p21. We systematically investigated the exon structure of
circANRIL in human cell lines and primary cells (Fig. 1a and
Supplementary Fig. 1). Using outward-facing primers and PCR
analysis of reverse-transcribed RNA, we observed several species
of circANRIL isoforms. The predominant circANRIL isoform
consisted of exons 5, 6 and 7, where exon 7 was non-canonically
spliced to exon 5 (Fig. 1a and Supplementary Fig. 1). We focused
on this isoform for detailed functional characterization and
further refer to it as circANRIL. CircANRIL was expressed in both
healthy and diseased human vascular tissues, as well as smooth
muscle cells (SMC) and monocyte/macrophages (Fig. 1b), which
play an important role in atherogenesis. CircANRIL levels were
relatively low compared with abundant housekeeping mRNAs
such as actin beta (ACTB; Fig. 1b), but comparable to the levels of
other human circular RNAs such as the previously described
CDR1as2 or circular HPRT1 (circHPRT1), which was identified in
the present study (Supplementary Fig. 2a). Nevertheless,
circANRIL RNA levels were on average 9.7-fold higher than
levels of linANRIL RNA when we analysed a panel of different
human cell types and tissues (Supplementary Fig. 2a,b).
CircANRIL was also more stable than linANRIL (Supplementary
Fig. 3). The latter is in line with previous reports on other circular
RNAs1,19. To determine the spatial distribution of circANRIL
expression in the context of vascular atherogenesis, we performed
RNA in situ hybridization using a circANRIL-specific probe
(Fig. 1c and Supplementary Fig. 4). We detected circANRIL in
SMC and in CD68-positive macrophages in human athero-
sclerotic plaques (Fig. 1c).
We next tested for an association of circANRIL expression with
the 9p21 genotype in a large cohort of patients with different
burden of coronary artery disease (CAD), as assessed by coronary
angiography17,20. Carriers of the CAD-protective haplotype at
9p21 showed significantly increased expression of circANRIL in
peripheral blood mononuclear cells (PBMC, n¼ 1,933; 14%
per protective A-allele; Fig. 1d) and whole blood (n¼ 970;
P¼ 1.86 10 7; 27% per allele; associations were calculated
using robust linear regression models). Differential expression
was replicated in endarterectomy specimens, where each
protective allele was associated with 13% higher circANRIL
expression (Fig. 1e). Importantly, the direction of effects for
circANRIL was inverse to the published results for linANRIL,
which was downregulated in patients carrying the 9p21 protective
genotype16,17. Consistent with these findings, circANRIL expres-
sion was inversely correlated with linANRIL expression in PBMC
of the CAD cohort (r¼  0.24; P¼ 3.72 10 29; linear
regression). We then tested for an association of circANRIL
with CAD burden. Patients with high circANRIL expression
developed less CAD (P¼ 0.047; odds ratio¼ 0.8; linear
regression) and highest circANRIL/linANRIL ratios were found
in patients free of CAD (P¼ 5.9 10 5; odds ratio¼ 0.75;
Fig. 1f; linear regression). Calculated by a Mendelian rando-
mization approach, the circANRIL/linANRIL ratio explained
a significant part of the observed association of 9p21 with
CAD (P¼ 0.002; linear regression). This establishes a causal
relationship between the genotype at 9p21, high circANRIL
expression and CAD protection. Taken together, these data
implied an atheroprotective role of circANRIL at 9p21, which was
inverse to the previously reported proatherogenic function of its
linear counterparts17.
CircANRIL controls apoptosis and cell proliferation in vitro.
We next wanted to test whether circANRIL was biologically active
and controlled cell functions related to atherosclerosis. To mimic
increased levels of circANRIL RNA, as observed in patients that
were protected from atherosclerosis, we set out to generate cell
lines stably overexpressing the circANRIL RNA consisting of
exons 5, 6 and 7. Since circularization of ANRIL was spliceosome-
dependent (Supplementary Fig. 5), we predicted that flanking
intronic sequences might be relevant for circularization and
constructed a vector, where exonic sequences were surrounded by
140 bp intronic sequences 50 of exon 5 and 30 of exon 7 (Fig. 2a
and Supplementary Table 1). On the basis of this approach
we succeeded to express circANRIL RNA in 12 of 30 (40%)
stably transfected HEK-293 cells, which was validated by
circANRIL-specific quantitative reverse transcription PCR
(qPCR) (Fig. 2b). On average, stably overexpressing circANRIL
cells had 16-fold higher circANRIL expression levels compared
with endogenous circANRIL. For functional studies, we selected
cell lines with a modest 3-fold overexpression to resemble a more
physiological situation (Fig. 2c–f). Corroborating our previous
results, measuring circANRIL RNA turnover rates following
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Figure 1 | CircANRIL expression in human vascular tissue and association with atheroprotection at 9p21. (a) Schematic of circANRIL at 9p21 and qPCR
assays for isoform specific quantification. CircANRIL contains exons 5, 6 and 7. Exon 7 is non-canonically spliced to exon 5. (b) qPCR analysis of circANRIL
expression in human tissues, primary cells and cell lines. Beta actin (ACTB), house-keeping gene; FB, adventitial fibroblasts; HEK, HEK-293 cell line; THP1
and MonoMac, human monocytic cell line. Analyses were done in RNA pools of at least three donors. (c) In situ hybridization of circANRIL in human
atherosclerotic plaque and co-localization with smooth muscle actin (SMA)-positive cells and macrophages (CD68). Sense control (CTR)-negative control.
Representative staining out of three biological replicates. (d) Association of circANRIL with 9p21 haplotypes in PBMC from CAD patients. Protective
(A, n¼498), heterozygote (H, n¼ 979) and risk (G, n¼456) haplotypes. (e) Association of circANRIL with 9p21 haplotypes A (n¼49), H (n¼ 114) and
G (n¼ 55) in endarterectomy specimens. (f) Association of circ/linANRIL ratio in PBMC with severity of CAD (No, n¼ 745; o50% stenosis, n¼ 392;
Z50% stenosis, n¼ 747). Data are given as mean±s.e.m., and associations were calculated using robust linear regression models.
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inhibition of RNA polymerase II transcription with actinomycin
D, the overexpressed circANRIL was more stable than linANRIL
(Supplementary Fig. 6).
Studies of key cell functions of atherogenesis in circANRIL-
overexpressing cells revealed increased apoptosis (Fig. 2c) and
decreased proliferation (Fig. 2d). Overexpression of the unrelated
circular RNA circHPRT1 (Supplementary Fig. 7 and Supple-
mentary Table 1) did not trigger these effects (Fig. 2c,d), ruling
out that proapoptotic and antiproliferative functions are generic
roles of all circular RNAs. In further support for the specificity of
the observed consequences of circANRIL overexpression, effects
could be reversed by small interfering RNA (siRNA)-mediated
downregulation of circANRIL RNA, but not by using linANRIL-
specific or scrambled siRNA controls (Fig. 2e,f and Supple-
mentary Fig. 8).
We next deleted exons 5–20 from the ANRIL locus in HEK-293
cells using CRISPR/Cas9 technology and established heterozy-
gous and homozygous knockout cell lines (Fig. 3a,b and Supple-
mentary Table 2). Deletion of exons 5–20 impairs linANRIL RNA
isoforms, which contain at least exons 5 and 6 (ref. 17). The
deletion also affects several circANRIL isoforms, including the
major isoform consisting of exons 5–7, which we are studying.
Our analysis revealed that loss of ANRIL conferred a gene dosage-
dependent reduction in apoptotic rate (Fig. 3c) and led to
increased cellular proliferation (Fig. 3d). We stress that increased
proliferation and reduced apoptosis cannot solely be ascribed to
either deletion of linANRIL RNAs nor to deletion of circRNAs.
For this reason, using an expression vector to restore circANRIL
but not linANRIL expression in these cell lines, we re-expressed
the major circANRIL isoform consisting of exons 5–7 in the
knockout cell line that misses exons 5–20. We showed that
presence of circANRIL alone was sufficient to increase cell
apoptosis (Fig. 3e) and to reduce proliferation (Fig. 3f) indicating
that circANRIL mediated its effects likely independent of
linANRIL at 9p21. Together, this genetic analysis demonstrates
that circANRIL is a physiologically relevant modulator of
apoptosis and proliferative capacity.
CircANRIL acts independent of CDKN2A/B and of miRNA
sponging. Previous work suggested that ANRIL regulated the
expression of the tumour suppressor genes cyclin-dependent
kinase inhibitors A and B (CDKN2A and B)21,22, located adjacent
to ANRIL’s genomic position. We therefore investigated whether
circANRIL affected the expression of these genes, but we detected
no significant changes (Fig. 4a). Furthermore, we observed that
linANRIL remained unaffected by overexpressing circANRIL
(Fig. 4a), excluding cis-regulation of 9p21 transcripts as mole-
cular effector mechanism. Other work has shown that circRNAs,
which were enriched for miRNA seeds, may serve as miRNA
sponges2,9. However, we only identified a maximum of three
binding sites for miR-4659a/b, miR-3184-3p and miR-5571-5p
(Fig. 4b) in circANRIL. Moreover, expression of these miRNAs
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Figure 2 | Atherosclerosis-related cell functions in circANRIL-overexpressing cells. (a) Schematic of the vector construct for circANRIL stable and
transient overexpression. RNA polymerase II (RNAP II). (b) ANRIL isoform expression in HEK-293 cells that stably express circANRIL, linANRIL or empty
vector (three biological replicates each). PCR of reverse-transcribed RNA, glyceraldehyde 3-phosphate dehydrogenase (GAPDH), house-keeping gene; OdT,
oligo(d)T primers; RH, random hexamer primers. (c) Apoptosis and (d) proliferation in HEK-293 cell line stably overexpressing circANRIL (pool of 3
biological replicates, and 8 and 12 technical replicates per condition, respectively), compared with overexpression of an unrelated circular RNA (circHPRT1).
Apoptosis (e) and proliferation (f) after RNAi against circANRIL or non-circANRIL or scrambled (SCR) siRNA control. Quadruplicate measurements per
condition. *Po0.05; **Po0.01; ***Po0.001. Comparison of multiple groups was done using analysis of variance, and Tukey was performed as post hoc test
in c,e. Two-tailed unpaired Student’s t-test in d,f. Data are given as mean±s.e.m.
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Figure 3 | Role of endogenous circANRIL on apoptosis and cell proliferation. (a) Schematic of CRISPR/Cas9-mediated knockout of ANRIL in HEK-293
cells. Genomic regions encompassing exons (Ex) 5–20 were deleted. Arrowheads indicate location and orientation of primers used for genotyping. (b) PCR
genotyping. Sequencing of PCR products from Ex5–20 assay validated successful deletion in mutant cell lines (Supplementary Table 2). (c) Apoptosis
and (d) proliferation in heterozygous and homozygous ANRIL knockout or control cell lines. As control, Cas9 was overexpressed without guide RNAs
(gRNAs). (e) Apoptosis and (f) proliferation in homozygous knockout cells following transient re-expression of circANRIL. *Po0.05; **Po0.01;
***Po0.001. (d) Heterozygous (***Po0.001) or homozygous (#Po0.05) ANRIL knockout versus control cell lines, respectively. Comparison of multiple
groups was done using analysis of variance, and Tukey was performed as post hoc test in c. Two-tailed unpaired Student’s t-tests were applied in d–f. Data


































































































































Figure 4 | CircANRIL does not regulate 9p21 protein-coding genes and lacks miRNA sponging activity. (a) Overexpression of circANRIL in HEK-293 cells
does not modulate endogenous linANRIL RNA abundance as measured by qPCR (left panel). Expression of p16INK4a and p14ARF, encoded by CDKN2A, and
p15INK4b, encoded by CDKN2B, in circANRIL-overexpressing cells (right panel) (pool of three biological replicates, quadruplicate qPCR measurements).
(b) Prediction of miRNA-binding sites in circANRIL using miRanda and TargetSpy algorithms. (c) miRNA expression normalized to miR-27b as measured by
qPCR (four biological replicates, quadruplicate measurements). (d) RNA immunoprecipitation (RIP) of AGO2. Analysis of precipitated RNAs: CDR1as,
MALAT1, positive controls; U1, negative control (RIP was performed in a pool of three biological replicates, quadruplicate qPCR measurements).
***Po0.001. NS, not significantly different. (analysis of variance, and Tukey as post hoc test). Data are given as mean±s.e.m.
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genome-wide expression arrays in circANRIL and control cells
did not support an induction of miRNA-regulated networks
(Supplementary Fig. 9; Gene Expression Omnibus GSE65392). In
addition, circANRIL did not bind to argonaute 2 (AGO2; Fig. 4d)
of the RNA-induced silencing complex, which is responsible for
miRNA-dependent degradation of target RNAs. These data
suggested that circANRIL controlled atheroprotective cell
functions through a novel molecular mechanism, independent
of cis-regulation at 9p21 and miRNA sponging.
CircANRIL is a component of a pre-ribosomal assembly complex.
Since linANRIL has protein-binding capacity17,21,22, we
performed a proteomic screen to identify potential circANRIL-
binding proteins (Fig. 5). To this end, we generated HEK-293 cell
lines with stable overexpression of circANRIL engineered to
contain RNA hairpin BoxB-sequences23 (circANRIL-BoxB;
Supplementary Fig. 10 and Supplementary Table 1). This
allowed capture of circANRIL-bound proteins in cellular lysates
via high affinity interaction of the BoxB RNA hairpin
with bacteriophage l transcriptional antiterminator protein
N (lN-peptide) coupled to beads (Fig. 5a–d). Circularization of
circANRIL was not impaired by the insertion of BoxB-sequences
(Supplementary Fig. 10). As controls for the capture, we used
protein extracts from HEK-293 cell lines with stable over-
expression of circANRIL without BoxB RNA hairpin sequences
(Fig. 5a). On the basis of quantitative reverse transcription PCR
analysis, we validated that circANRIL was highly enriched
following bead-mediated capture (Fig. 5b), demonstrating that
our isolation strategy was specific and selective. Capture
experiments were performed in quadruplicates and we used
2 mg of precipitated protein from each of the two conditions
for label-free mass spectrometric analyses. Here we detected 32
proteins with significant enrichment in extracts from circANRIL-
BoxB-overexpressing cells compared with extracts from control
cells (Fig. 5c,d and Supplementary Table 3). The majority of
identified proteins was involved in ribosome biogenesis and
assembly (38%) and regulation of RNA splicing (16%) (Fig. 5c)
suggesting that circANRIL may play a role in these important
cellular processes. Strongest binding was determined for nucleolar
protein 14 (NOP14, Fig. 5d), which is involved in the formation
of the nucleolar 40S ribosomal subunit24, and for pescadillo
zebrafish homologue 1 (PES1, Fig. 5d), which is a component of
the PES1–BOP1–WDR12 (PeBoW) complex. This complex is
homologous to yeast Nop7-Erb1-Ymt1 (refs 25,26) and a key
regulator of large 60S ribosome subunit biogenesis27,28. The
PeBoW complex assembles with pre-ribosomes and binds to
precursor rRNA (pre-rRNA), thereby facilitating the processing
of 47S pre-rRNA to mature 28S and 5.8S rRNA by
exonucleases25,29,30. Block of proliferation 1 (BOP1), which was
demonstrated to bind PES1 (refs 26,30), was also present in
circANRIL-BoxB extracts, as well as ribosome biogenesis protein
BRX1 homologue (BRIX1) and nucleolar and coiled-body
phosphoprotein 1 (NOLC1), two other PeBoW complex-
associated proteins27 (Fig. 5d).
To corroborate our mass spectrometric analysis by an
independent method, we chose to analyse circANRIL–protein
interactions by RNA immunoprecipitation (RIP). qPCR analysis
after RIP revealed the interaction of circANRIL RNA with the
PeBoW complex members PES1 and NOP14, where circANRIL
binding to PES1 was the strongest interaction tested (Fig. 5e).
PES1 binding was not detected for circularized HPRT1
(circHPRT1), indicating that the binding of circANRIL to PES1
was not due to a generic interaction of PES1 with all species of
circular RNAs in a cell (Fig. 5e). lN-peptide-mediated pull-down
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Figure 5 | Identification of circANRIL-binding proteins. (a) Schematic of lN-peptide-mediated capture of circANRIL-BoxB from cellular lysates of stably
overexpressing HEK-293 cell lines, and label-free mass spectrometric quantification. Experiments were performed in a pool of three biological replicates
(quadruplicate measurements). (b) Quantification of RNAs by qPCR after lN-peptide capture (quadruplicate measurements). (c) Summary of circANRIL-
BoxB-bound proteins according to annotated (KEGG, GO) and published functions. (d) Volcano plot of label-free quantification (LFQ) of circANRIL-BoxB-
bound proteins compared with circANRIL input control. (e) RIP of PES1, NOLC1, NOP14 and mouse IgG (mIgG) control (RIP was performed in a pool of three
biological replicates, quadruplicate measurements). (f) Western blot of PES1 after lN-peptide-mediated circANRIL-BoxB capture using nuclear extracts
from indicated cell lines.
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blotting validated circANRIL binding to PES1 protein (Fig. 5f) but
not to NOP14. We therefore focused subsequent functional
studies on PES1 as main circANRIL-interacting protein.
CircANRIL controls pre-rRNA maturation and nucleolar stress.
PES1 is essential for PeBoW complex function, and inhibition of
this complex leads to accumulation of premature rRNA isoforms
(Supplementary Fig. 11)29,30. Using isoform-specific qPCRs31, we
detected a significant accumulation of 36S and 32S pre-rRNA in
circANRIL-overexpressing HEK-293 cell lines but not in
circHPRT1-overexpressing cells (Fig. 6a). Expression levels of
47S pre-rRNA and 7SL RNA, which is independently transcribed
by RNA polymerase III, were not altered in either cell line
(Fig. 6a). Corroborating results from our qPCR analysis, northern
blotting revealed an accumulation of 32S and 36S pre-rRNAs in
circANRIL-overexpressing cells (Supplementary Fig. 12). Effects
on pre-rRNAs could be reversed by siRNA against circANRIL
(Fig. 6b) implying that circANRIL negatively regulated PeBoW
activity and rRNA maturation. This regulation of ribosome
maturation is a previously undescribed function for circANRIL
and a yet undescribed role for circular RNAs in general.
It is well established that inhibition of rRNA maturation leads
to impaired ribosome biogenesis and induction of nucleolar
stress32, which may be evidenced by small nucleoli, nucleolar
disorganization33 and p53 stabilization32,34. Indeed, immuno-
fluorescent stainings of PES1 (Fig. 6c and Supplementary
Fig. 13a) and BOP1 (Supplementary Fig. 13b) revealed signi-
ficantly more (Fig. 6d) and smaller (Fig. 6e) nucleoli in
circANRIL-overexpressing HEK-293 cells, providing evidence
for increased nucleolar stress. Notably, we did not detect an
increase in nucleolar number nor a decrease of nucleolar size
when we stably overexpressed circHPRT1 (Fig. 6d,e), providing
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Figure 6 | rRNA maturation defects and nucleolar stress in circANRIL-overexpressing cells. (a) Relative quantification of pre-rRNA in circANRIL- or in
circHPRT1-overexpressing HEK-293 cells using isoform-specific qPCRs (RNA from a pool of three biological replicates, quadruplicate measurements).
(b) Pre-rRNA levels after RNAi against circANRIL or using scrambled siRNA control (quadruplicate measurements per condition). (c) Immunofluorescent
staining of PES1 in circANRIL- or in circHPRT1-overexpressing HEK-293 or empty vector control cells. Quantification of (d) nucleoli and (e) nucleolar size in
circANRIL- or circHPRT1-overexpressing or empty vector control cells (*** Po0.001). Data are given as mean±s.e.m. (analysis of variance, and Tukey as post hoc
test). (f) Immunofluorescent staining of p53 (red) in circANRIL- or circHPRT1-overexpressing or empty vector control cells. (g) Schematic of transcriptome and
proteome analyses in circANRIL-expressing HEK-293 cells and in control cells by genome-wide expression arrays and by pulseSILAC, respectively. For results of
pathway analyses and procedure, see Supplementary Tables 4–6 and Methods section, respectively. L/M/H, light/medium/heavy medium.
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Using immunofluorescent stainings, we also detected a significant
accumulation of p53 in the nuclei of circANRIL-overexpressing
cells (Fig. 6f and Supplementary Fig. 13c). Activation of p53 was
further corroborated by proteomic analyses in cell cultures of
circANRIL and control cell lines after pulse stable isotope
labelling (pulseSILAC), as well as by transcriptome-wide RNA
expression analyses (Fig. 6g), which indicated a significant
activation of p53 signalling both, at the protein and at the
mRNA level (Supplementary Tables 4–6; Gene Expression
Omnibus GSE65392).
CircANRIL binding to PES1 prevents rRNA maturation.
Although circANRIL and ribosomal RNA belong to different
families of lncRNAs, we observed significant sequence homology
(Fig. 7a and Supplementary Table 7). Since circANRIL (Fig. 5)
and ribosomal RNA both bind to PES1 (ref. 25), we hypothesized
that circANRIL occupied pre-rRNA-binding sites at PES1, thereby
inhibiting exonuclease-mediated processing and maturation
of ribosomal RNA. Using two independent algorithms for
RNA–protein interaction, circANRIL-PES1 binding was
predicted to be mediated through RNA domains with high
pre-rRNA sequence homology (Fig. 7b and Supplementary
Table 7) forming RNA stem loop structures (Fig. 7c), and
through the N- and C-terminal domains of PES1 protein
(Fig. 7d), respectively. These protein domains are enriched for
lysine-rich amino-acid motifs with protein–RNA binding
potential35 and have structural similarity to nuclear localization
signals (NLSs). Previous work has shown that PES1’s NLSs are
not required for nucleolar localization of PES1 but important for
PeBoW complex function26,29.
To investigate whether circANRIL bound to PES1 at the
predicted protein domains, we performed protein immunopreci-
pitation of full-length and truncated PES1 (PES1D1-54 or
PES1D446–588, respectively; Fig. 7d,e, Supplementary Fig. 14 and
Supplementary Table 8). We only detected circANRIL binding
when the C-terminal PES1 protein domain (aa 446–588) was
present (Fig. 7e). This domain was also required for 47S and 36S
pre-rRNA binding and circANRIL prevented pre-rRNA binding to
some extent (Fig. 7f and Supplementary Fig. 15). Importantly, full-
length but not truncated PES1 restored rRNA maturation in
circANRIL-expressing cells (Fig. 7g) and reduced p53 accumulation
(Fig. 7h), apoptosis (Fig. 7i) and cellular proliferation (Fig. 7j).
Together, these data establish circANRIL as a molecular
inhibitor of PES1 by binding at the C-terminal domain of
PES1. This may, at least in part, explain the effects of circANRIL
in rRNA maturation, nucleolar stress and atheroprotective cell
functions.
Translation of circANRIL molecular effects to human disease.
ANRIL is evolutionary not conserved between species, and exons
5–7, which are contained in circANRIL, are primate-specific18.
Consequently, no expression of circANRIL was detected in mouse
tissues using qPCR preventing studies in mouse models. To
translate our in vitro findings to a physiologically relevant in vivo
context, we performed functional studies in human primary
SMC and human induced pluripotent stem cell (iPSC)-derived
macrophages and conducted association studies in human disease
cohorts (Fig. 8). CircANRIL overexpression in SMC (Fig. 8a–f)
increased the numbers of nucleoli (Fig. 8a,b), reduced nucleolar
size (Fig. 8a,c), and led to an accumulation of pre-rRNAs
(Fig. 8d). Consequently, circANRIL induced apoptosis (Fig. 8e)
and decreased cell proliferation (Fig. 8f). Using SMC of different
patients, we demonstrated that cells with higher endogenous
circANRIL expression showed a stronger induction of apoptosis
and a reduced proliferative capacity as well (Fig. 8g,h). In
iPSC-derived macrophages (Supplementary Fig. 16) circANRIL
overexpression also caused an accumulation of pre-rRNAs
(Fig. 8i) and induced apoptosis (Fig. 8j), thereby confirming
that circANRIL-associated induction of nucleolar stress also
occurs in cells that are relevant in atherogenesis in vivo.
Further in vivo evidence was obtained from human athero-
sclerotic plaques (n¼ 218) (Fig. 8k). Here we observed significant
correlations of circANRIL with 36S (rs¼ 0.17, P¼ 0.003,
Mann–Whitney U-test) and 32S pre-rRNA abundance
(rs¼ 0.21, P¼ 0.0003; Mann–Whitney U-test) but not with 47S
pre-rRNA (rs¼  0.01, P¼ not significant; Mann–Whitney
U-test) or with 7SL control RNA abundance (rs¼ 0.09, P¼ not
significant; Mann–Whitney U-test). This indicates that high
circANRIL levels led to an accumulation of pre-rRNA in human
vascular tissue. In this cohort, 32S pre-rRNA was also elevated in
patients carrying the CAD-protective allele at 9p21 (Fig. 8k),
linking the atheroprotective genotype with high circANRIL
expression (Fig. 1d–f) and pre-rRNA accumulation in vivo. To
further translate our findings, we performed pathway analyses of
genome-wide expression data, obtained from PBMC of 1,933
subjects of our cohort of patients with CAD20. While no
transcripts were significantly associated with the 9p21 genotype
at a genome-wide level17, gene set enrichment analyses of
circANRIL-correlated genes (n¼ 1,864; pr0.001 (Ingenuity
Pathway Analysis)) revealed induction of p53 signalling as the
most significantly enriched pathway (Table 1) demonstrating that
circANRIL also promoted nucleolar stress in vivo. Taken together,
genome-wide expression and pathway analyses in large human
CAD cohorts, pre-rRNA expression levels in human athero-
sclerotic plaques and functional studies in relevant human cells
validate a circRNA effector mechanism, where circANRIL
controls pre-rRNA maturation and nucleolar stress and thereby
may act as protective factor against human atherosclerosis.
Discussion
Our work provides a proof of concept for a long non-coding
circRNA as a molecular regulator of rRNA maturation and of key
cellular functions relevant to human disease. Results of this study
extend our current knowledge about the molecular mechanisms
of circRNAs, previously including the escape from translation8
and miRNA sponging2,9, to control of ribosomal RNA
maturation through circRNA-protein interaction. We show that
circANRIL binds to the C-terminal lysine-rich domain of PES1,
thereby preventing pre-rRNA binding and exonuclease-mediated
rRNA maturation25. Consequently, circANRIL impairs ribosome
biogenesis, leading to activation of p53 and a subsequent increase
in apoptosis and decrease in proliferative rate. Together, this
pathway may promote atheroprotection by culling
overproliferating cell types in atherosclerotic plaques.
PES1 is a nucleolar protein that is known to assemble in the
PeBoW complex, which consists of PES1, BOP1 and WDR12.
This complex is central for ribosome biogenesis and essential for
life from yeast to mammals26,36. Additional support for an
important role or the PeBoW complex in human atherosclerosis
comes from genome-wide association studies of CAD, which
independently identified WDR12 as an atherosclerosis modifier
gene13,36,37. Human PES1 is a 588 amino-acid protein38, and
previous work has shown that the central BRCT motif is essential
for the incorporation of PES1 into the PeBoW complex and
nucleolar localization30. In contrast, deletion of the C-terminal
domain, containing NLS motifs, did not affect nucleolar
localization but blocked rRNA maturation29. This was accom-
panied by changes in nucleolar morphology, inhibition of
proliferation and induction of p53 in proliferating cells29.
Results of the current work establish the C-terminal domain of
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PES1 as the binding site of both circANRIL and pre-rRNA.
circANRIL binding prevented exonuclease-mediated processing of
pre-rRNA, causing a dominant-negative phenotype as observed
for the C-terminal deletion mutants of PES1 (Fig. 7g-j). It is
remarkable that circANRIL can interfere with rRNA processing
despite the relatively low abundance of detectable circANRIL
RNA in the cell. On the basis of the published copy number of
CDR1as in HEK-293 cells2 and our finding that circANRIL
is 4–6 times higher expressed than CDR1as in these cells
(Supplementary Fig. 2a), we estimate that the copies of
circANRIL RNA per HEK cell will amount to 800–1,000. As a
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Figure 7 | Molecular mechanism of circANRIL controlling PES1 function. (a) Homology of circANRIL and precursor 47S rRNA (blue boxes) determined
by BLASTn algorithm. (b) Prediction of RNA–protein interaction of circANRIL with PES1 using the catRAPID algorithm. Homology regions (HR1–HR5)—
predicted RNA–protein interaction motifs in circANRIL. (c) Secondary structure prediction and HR1–5 of circANRIL using the Vienna RNA package69. (d)
Schematic of PES1 with functional protein domains. Wild-type PES1 (PES1-WT) and two mutants lacking the 50 (PES1D1–54) or the 30 (PES1D446–588)
lysine-rich NLSs. (e) Immunoprecipitation (IP) of PES1 isoforms from HEK-293 cells and quantification of RNA by qPCR (IP was performed in a pool of three
biological replicates, quadruplicate measurements). (f) Pre-rRNA binding to PES1-WTand PES1D446–588 in circANRIL-overexpressing and control cells (IP
was performed in a pool of three biological replicates, quadruplicate measurements). (g) Pre-rRNA and 7SL control RNA in circANRIL-expressing HEK-293
cells after transient PES1-WT or PES1D446–588 overexpression (pool of three biological replicates, quadruplicate measurements). (h) p53 western blot,
(i), apoptosis and (j) cell proliferation in circANRIL-overexpressing HEK-293 cells with transient overexpression of PES1-WT or of PES1D446–588.
Quadruplicate measurements per condition. *Po0.05; **Po0.01; ***Po0.001. NS, not significantly different. Analysis of variance, and Tukey as post hoc
test in e,g and i. Two-tailed unpaired Student’s t-tests were applied in f,j. Data are given mean±s.e.m.
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circANRIL copies relative to copies of PES1 protein might
determine the efficacy of blocking PES1-dependent rRNA
processing. Assuming a median abundance of 8,000 protein
molecules per cell for an average protein in a typical tissue culture
line39, a stoichiometry of circANRIL RNA:PES1 protein of 1:10
can be estimated. These data suggest that PES1 might be
inactivated by circANRIL at a certain percentage even in native,
non-overexpressing cells. One might speculate that thereby,
circANRIL may impair PES1-mediated rRNA processing and
ultimately impair protein translation rate and cell growth. We
also base this hypothesis on a previously published study where a
dominant-negative phenotype has been revealed for a C-terminal
deletion mutant of PES1, such that mutant PES1 incorporated
into the PeBoW complex inactivated the complex and blocked
processing of the 32S pre-rRNA, leading to stabilization of p53
and to cell cycle arrest29. Notably, we also detected a mosaicism of
circANRIL expression levels in primary SMC and macrophages in
vascular tissues (Fig. 1), suggesting that circANRIL’s roles in
curbing atherogenesis may have to be investigated on a single-cell
level to fully appreciate circANRIL function.
Despite the fact that we overexpressed circANRIL only
threefold in HEK-293 cells, it is also evident that the
physiologically occurring differences in circANRIL expression
observed in our human studies were smaller than in the
overexpressing cell lines. Consequently, they are likely to be
accompanied by smaller biological effects as well. Nevertheless, it
is important to recognize that effects in overexpressing cell lines
could be replicated in human primary cells with the same
directions of effects (Fig. 8). Moreover, we identified the same
0
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Figure 8 | Translation of circANRIL molecular mechanisms in human primary cells and human cohorts. (a) CircANRIL overexpression in primary human
SMC using the green fluorescent protein (GFP)-encoding, bicistronic pBI-CMV2 vector (green; Fig. 2a) and immunofluorescent staining of PES1 (red).
Quantification of nucleoli (b) and nucleolar size (c) in circANRIL-overexpressing (GFPþ) SMC and circANRIL-negative (GFP) cells. AU, arbitrary units.
(d) Quantification of pre-rRNAs following circANRIL overexpression in SMC. (e) Apoptosis and (f) proliferation in SMC transfected with circANRIL.
Quadruplicate measurements per condition. Correlation of endogenous circANRIL expression in human SMC with (g) apoptosis and (h) proliferation (n¼ 5;
quadruplicate measurements each). (i) Quantification of pre-rRNA following circANRIL overexpression in iPSC-derived macrophages (Supplementary
Fig. 16). (j) Apoptosis in iPSC-derived macrophages transfected with circANRIL. LI, luminescence intensity. Quadruplicate measurements per condition.
(k) Association of 32S rRNA expression with 9p21 A (n¼49), H (n¼ 114) and G (n¼ 55) haplotypes in endarterectomy specimens. ***Po0.001.
Two-tailed unpaired Student’s t-tests were applied in b,e,f and j, and Mann–Whitney U-testing in k. Data are given mean±s.e.m.
Table 1 | Upstream regulator analysis of circANRIL-










Transcripts correlated with circANRIL expression (Po0.001; n¼ 1,864, Ingenuity Pathway
Analysis) were included in the analysis.
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molecular effector mechanisms of circANRIL in stably over-
expressing cell lines and human cohorts, where high circANRIL
led to the accumulation of pre-rRNA and p53 activation. Since
atherosclerosis develops throughout life, it is plausible that subtle
genotype-directed gene expression differences modulate the risk
to develop symptomatic atherosclerotic cardiovascular disease at
a higher age. Therefore, studies in overexpressing cell lines might
be viewed as a time-lapse of the protective effects of circANRIL
seen in individuals carrying the 9p21 atheroprotective genotype
free of atherosclerosis (Figs 1 and 8).
Recently, substantial progress has been made in understanding
the molecular mechanism of RNA circularization. It is thought
that exonic circRNAs are generated by so called ‘back-splicing’,
enhanced by complementary base pairing of inverted repeats in
the circRNA flanking introns1,5,6,19,40,41. Current work has also
revealed a growing number of proteins affecting exon circu-
larization41–43, and the proportion of circular versus linear
transcripts may depend on the presence of specific intronic
binding sites for these factors44. Even though the mechanism of
ANRIL circularization has not been the scope of this work, it is
likely that single-nucleotide polymorphisms contained in the
9p21 haplotype are responsible for differential circANRIL
formation. Since low linANRIL and high circANRIL expression
was associated with atheroprotection at 9p21, our results also
underscore the importance of a balanced expression of linear and
circular RNA transcripts. More generally, our results support a
concept where circularization might be protective to escape linear
RNA function, which has been associated with the onset and
progression of diseases16,17,45.
Soon after the identification of the 9p21 locus by human
genome-wide association studies12,13, a mouse model with a 70 kb
deletion at chromosome 4 (Chr4D70kb/D70kb), representing the
mouse orthologue of the human 9p21 risk haplotype, has been
published46. While the deletion had no effect on atherosclerosis,
in vitro studies revealed increased proliferation of isolated aortic
SMC from Chr4D70kb/D70kb animals46. The direction of effects
was comparable to our results of the knockdown of circANRIL,
which increased proliferation as well. It is, however, unlikely that
the effects observed in the Chr4D70kb/D70kb mouse model are
related to ANRIL, because phylogenetic analyses revealed that
ANRIL is absent in mice and fully developed only in certain
primates, including humans18. In line with this, we detected no
ANRIL expression in mouse tissue, and therefore, mouse models
are not informative for the study of ANRIL. Instead, results of
our study support a recent gain of function of primate-specific
non-coding circRNA in controlling evolutionary conserved
protein complexes. Several RNAs without evident protein-
coding function were shown to co-localize with ribosomes47,
suggesting that regulation of ribosome biogenesis by lncRNAs
might be a broader phenomenon in humans than previously
anticipated.
But how may circANRIL-mediated inhibition of rRNA
processing be linked to atheroprotection? A major finding of
the current study was that circANRIL induced ‘nucleolar stress’
(Figs 6–8) with subsequent stabilization of p53. Oncologists are
now considering nucleolar stress strategically as a potential
anticancer therapy32,48. In a similar fashion as cancer,
atherosclerosis may be viewed as a proliferative disease.
However, the role of proliferation and apoptosis in
atherosclerosis is multi-facetted and inhibition of cellular
proliferation and induction of apoptosis is not necessarily
atheroprotective under all circumstances. For instance, while
apoptosis in endothelial cells (EC) is proatherogenic, apoptosis
in macrophages might attenuate early progression but can also
induce secondary inflammation and plaque rupture49. The net
effect of these individual mechanisms is difficult to determine
experimentally. Nevertheless, one of our key observations was
that p53 was induced on circANRIL overexpression, and mouse
models have demonstrated that p53 is atheroprotective50,51,
providing further evidence for an atheroprotective net effect of
circANRIL.
Taken together, our data suggest circANRIL as a potential
therapeutic target for the treatment of atherosclerosis, since it
might promote antiatherogenic cell functions and is particularly
stable against degradation. High stability seems to be a common
feature of circRNAs1,19, which might therefore serve as attractive
novel therapeutic targets for human diseases in more general
terms.
Methods
Study cohorts. Association analysis of gene expression was performed in samples
of the LIFE Heart Study (n¼ 2,280), a cross-sectional cohort study of patients
undergoing coronary angiography for suspected CAD20. The study has been
approved by the Ethics Committee of the Medical Faculty of the University Leipzig
(Reg. No 276-2005). Human endarterectomy specimens (n¼ 218) were collected in
a cohort of patients undergoing vascular surgery, and the utilization of human
vascular tissues was approved by the Ethics Committee of the Medical Faculty Carl
Gustav Carus of the Technical University Dresden (EK316122008)17,52. Human
primary cells (EC, SMC and adventitial fibroblasts (FB)) from non-diabetic,
non-smoking patients and liver samples were obtained and experimental
procedures were performed within the framework of the non-profit foundation
Human Tissue and Cell Research53. Written informed consent was obtained from
all subjects.
DNA and RNA isolation and 9p21 genotyping. Isolation of DNA and RNA from
PBMC, human primary tissues and cells was performed using TRIzol reagent
(Thermo Fisher Scientific)16,17. RNA from nuclear and cytoplasmic fractions and
whole-cell lysates for RNA distribution studies were prepared using the PARIS
Kit (Ambion) according to the manufacturer’s instructions. Chr9p21 protective (A)
and risk (G) haplotypes (Fig. 1d,e) were defined by single nucleotide poly-
morphisms rs10757274, rs2383206, rs2383207 and rs10757278 (refs 16,52).
Reverse transcription. RNA from human samples and cell lines was reverse
transcribed using random hexamer primers (Roche). For validation of circular
RNA overexpression, RNA was reverse transcribed with random hexamer
primers (Roche Life Sciences), detecting linear and circular RNA transcripts
and oligo(OdT) primers (Roche Life Sciences), for detecting linear transcripts
containing poly-A tails. For miRNA quantification, RNA was reverse transcribed
using the miScript II RT Kit (Qiagen).
PCR and qPCR. The AmpliTaq DNA Polymerase (Life Technologies) was used for
PCR and qPCR reactions. PCR reactions for amplification of circANRIL were
performed in cDNA from SMC, FB, EC, MonoMac and HEK-293 cells, with
outward-facing primers in ANRIL exon 6 (ref. 14). No PCR products were
amplified in EC. PCR products were cloned using the TOPO TA Cloning Kit
(Life Technologies) and sequenced with an automated DNA sequencer (Applied
Biosystems). Quantification of gene expression was performed on a ViiA 7
Real-Time PCR System (Life Technologies) according to published protocols and
normalized to plasmid standard curves17. PCR products were visualized using the
Lonza FlashGel System (Biozym). Primers and probes for amplification of
linANRIL (synonymous to ANRIL ex18-19 in ref. 17), U1, beta actin (BA), GAPDH,
CDKN2A (p14ARF, p16INK4a), CDKN2B (p15INK4b)17, MALAT1 (ref. 54)
and CDR1as (ref. 2) were used according to published protocols. Primers
and probes for circANRIL (ex7-5), linþ circANRIL (ex6-7), circHPRT1 (ex6-2),
linþ circHPRT1 (ex2-3), PES1, sex-determining region Y-box 2 (SOX2) and v-maf
avian musculoaponeurotic fibrosarcoma oncogene homologue (MAF)55 are given
in the Supplementary Table 9. Expression of 47S, 36S and 32S rRNA and 7SL RNA
control was determined according to ref. 31 using the KAPA SYBR FAST reagent
(PeqLab). Quantification of miRNAs Hs_miR-3184-3p_1 (MS00041944, Qiagen),
Hs_miR-4659b-3p_1 (MS00040390, Qiagen) and Hs_miR-5571-5p_1
(MS00038360, Qiagen) was performed with the miScript SYBR Green PCR Kit
(Qiagen) and normalized to Hs_miR-27b_2 (MS00031668, Qiagen).
Genome-wide expression profiling. Illumina HumanHT-12 v4 BeadChips arrays
were used for expression profiling in human PBMC (n¼ 2,280) of the LIFE Heart
Study and in cell lines with stable circANRIL overexpression (n¼ 3) and vector
control (n¼ 3). For data from cell lines, bead-level data preprocessing was done in
Illumina GenomeStudio followed by quantile normalization and background
reduction according to standard procedures in the software. Preprocessing of
expression data in PBMC of the LIFE Heart Study comprised selection of expressed
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features, outlier detection, normalization and batch correction17. Gene expression
data have been deposited at Gene Expression Omnibus (GSE65392).
Expression vectors. CircANRIL, circANRIL-BoxB, BoxB and circHPRT1
sequences were synthesized (Eurofins Genomics) with adjacent 50- and 30-140 bp
intronic sequences (Fig. 2a and Supplementary Table 1) and cloned in the
bicistronic pBI-CMV2 (Clontech) vector allowing parallel expression of a green
fluorescent protein and RNA transcripts. Stable cell lines were generated through
co-transfection with a neomycin-encoding vector17. PES1 wild type (PES1-WT)
and truncated PES1 (PES1D1–54 and PES1D446–588, respectively; Fig. 6f and
Supplementary Table 8) were cloned in the pmCherry-N1 vector (Clontech)
encoding a neomycin resistance and allowing overexpression of PES1 fused to a
red fluorescent protein (RFP).
Cell culture and functional studies. HEK-293 (DMSZ, ACC305) were cultured in
DMEM (Life Technologies) containing 10% fetal calf serum (FCS, Biochrom) and
1% penicillin/streptomycin (P/S; Life Technologies). MonoMac cells (DSMZ,
ACC124) were cultured in RPMI 1640 (Biochrom) containing 10% FCS, 1% P/S,
1% MEM (Life Technologies) and 1% OPI (Sigma) . Primary arterial SMC (n¼ 5)
and FB (n¼ 5) were cultured in Smooth Muscle Cell Growth Medium 2
(PromoCell) and Fibroblast Growth Medium (PromoCell), respectively. iPSC were
cultured using using mTeSR 1 Medium (STEMCELL Technologies)56 and
differentiated into macrophages55. For generation of stably overexpressing cells,
HEK-293 were transfected with ANRIL-pBI-CMV2 vectors (Clontech) and
neomycin-encoding vector, cells were selected with geneticindisulfate (G418,
Roth)17 and overexpression was validated using specific qPCRs. At least three cell
lines were generated per isoform and vector control, respectively. Knockout of the
9p21 locus in HEK-293 cells was accomplished using CRISPR/Cas9 technology56
with guide RNAs (Fig. 3a and Supplementary Table 10) and controlled using
PCR and sequencing (Fig. 3a,b; Supplementary Tables 2 and 10). Transient
transfection of HEK-293 9p21 mutant, primary SMC and iPSC-derived
macrophages was performed using Lipofectamine 2000 (Life Technologies) or
Nucleofector technology (Lonza) according to the manufacturer’s instructions.
Cellular proliferation was determined using CellTiter-Glo Luminescent Cell
Viability Assay (Promega). Apoptosis was induced by staurosporine (0.25 and
0.5 mM; Calbiochem) and quantified by a caspase-3 activity assay (Caspase-Glo 3/7
Assay; Promega). Measurements were performed on the SpectraMax Paradigm
Multi-Mode Microplate Reader (Molecular Devices). Transfection of siRNA was
performed using Lipofectamine 2000 (Life Technologies) or Nucleofector
technology (Lonza) according to the manufacturer’s instructions. The following
siRNAs were used for downregulation of ANRIL isoforms: non-circANRIL:
n272158, exon 1 (Life Technologies); circANRIL: 2046125, exon 7 (Qiagen);
GAPDH (4390849; Life Technologies); and SCR control (Silencer Select
Negative Control No. 1 siRNA, 4390843; Life Technologies). siRNA-mediated
downregulation of ANRIL or overexpression of ANRIL and PES1 isoforms was
validated by isoform-specific qPCRs and western blotting, respectively. All
experiments were performed in quadruplicates using 2–4 biological replicates. To
assess RNA stability, cells were incubated with actinomycin D (50 ngml 1; Sigma)
for up to 72 h. For pre-mRNA splicing inhibition, cells were incubated with
isoginkgetin (Calbiochem) for 24 h.
Antibodies. Antibodies for western blotting, immunofluorescent staining and RIP,
and secondary antibodies are given in Supplementary Table 11.
Western and northern blotting. Nuclear and cytoplasmic fractions and whole-
cell lysates for western blotting were prepared using the PARIS Kit (Ambion) and
run on NuPAGE Novex 4–12% Bis-Tris Protein Gels (Life Technologies). Primary
and secondary peroxidase-labelled antibodies are given in Supplementary Table 11,
AceGlow-Solution (PeqLab) was used for visualization of the chemiluminescent
light signal of protein bands (white on black background) using the Fusion-FX7
Advance system (PeqLab). For northern blot analysis, 2 mg of total RNA isolated
from HEK-293 cell lines with stable circANRIL or vector overexpression were
separated on an 1% agarose gel containing formaldehyde and blotted onto a
Hybond-Nþ membrane (GE Healthcare). rRNA molecules were detected using
the 30-BITEG-labelled probes ITS1 and ITS2 (ref. 36) and streptavidin-POD
(Roche). Western and northern blots were repeated three times and representative
experiments are shown in the manuscript.
In situ hybridization and immunohistochemical stainings. In situ RNA
hybridization was conducted in formaldehyde-fixed endarterectomy tissues with
digoxygenin (DIG)-labelled RNA probes (Roche Life Sciences) against circANRIL
(exons 7–5–6; 381 bp) and sense negative control according to ref. 57. Anti-DIG-
AP (Roche Life Sciences) was used as secondary antibody and staining was
developed with NBT/BCIP solution (Roche Life Sciences). For dot blot analysis
(Supplementary Fig. 12), RNA was spotted onto a Hybond-Nþ membrane
(GE Healthcare) and detected using a DIG-labelled probe against circANRIL and
the anti-DIG-HRP antibody (PerkinElmer). Immunohistochemical staining of
CD68 and SMA was performed using the ImmPRESS HRP Anti-Rabbit and
Anti-Mouse Ig Polymere Detection System (Vector Laboratories) and 3,30-diami-
nobenzidine52. In situ hybridization and immunohistochemical stainings were
performed three times and representative images are shown in the manuscript.
Immunofluorescent stainings. Cells were fixed with 1% formaldehyde and
permeabilized with 0.3% Triton X-100. After blocking with 5% goat normal
serum (Jackson ImmunoResearch Laboratories), primary antibodies were applied
overnight at 4 C at a dilution 1:100. Secondary antibodies were applied at a
dilution 1:500 for 1 h at room temperature. Nuclei were stained with Hoechst
33342 (Sigma Aldrich) and samples were mounted with Fluorescence Mounting
Medium (Dako). Pictures were taken with an Olympus Fluorescence Microscope
OlympusBX40 and an Olympus XM10 camera. Immunoflurescent stainings were
performed three times and representative images are shown in the manuscript.
Nucleoli were counted per cell and nucleolar size was determined in px2 with the
LAS V4.2 software (Leica).
kN-Peptide-mediated pull-down of circANRIL-bound proteins. Pull-down of
circANRIL-BoxB (Supplementary Fig. 3; ref. 23) was performed with the
N-terminal domain (amino acids 1–22) of the lN-peptide coupled to d-desthio-
biotin (Intavis Peptide Services) according to ref. 58. As controls, cellular lysates
from cell lines with stable overexpression of circANRIL were used. Streptavidin
beads (Dynabeads MyOne, Life Technologies) were prewashed according to the
manufacturer’s instructions and blocked with 1mg tRNA per ml and 1mg BSA per
ml in LN-buffer (20mM Tris-HCl (pH 7.5), 0.1% NP40, 150mM NaCl, 1mM
MgCl2, 0.2mM EDTA and 1mM dithiothreitol). Cellular lysates (1mg total
protein) were incubated with 100 ml streptavidin beads overnight at 4 C in 1,000ml
LN-buffer, 100 mg tRNA per ml, 1U RNasin per ml and 10% glycerine. After
washing with 5 with LN-buffer, 3 with LN-buffer, 500mM NaCl and 2
with LN-buffer containing 250mM LiCl instead of NaCl, circANRIL-BoxB-bound
proteins were eluted with eluted with 100ml Urea buffer (2M urea and 50mM Tris
(pH 7.5)) supplemented with 1mM dithiothreitol and 5 mg ml 1 trypsin and LysC.
After alkylation with 5mM iodoacetic acid (IAA), proteins were proteolytic
digested with trypsin and LysC for 24 h. Peptides were acidified, loaded on
SDB-RPS material and eluted and dried59. Peptides were resuspended in buffer
A* (2% acetonitrile (ACN) and 0.1% trifluoroacetic acid (TFA)) and were briefly
sonicated (Branson Ultrasonics, Ultrasonic Cleaner Model 2510) before mass
spectrometric analyses. CircANRIL-BoxB RNA was eluted with 1% SDS, 20mM
Tris-HCl (pH 7.0), 0.1mM EDTA at 99 C for 15min, extracted with TRIzol
(Life Technologies)/CHCl3 and precipitated with isopropanol. RNA was reverse
transcribed with random hexamer primers and analysed by qPCR.
RNA immunoprecipitation. RIP was performed using antibodies given in
Supplementary Table 11 (ref. 17). RFP-Trap_M (rtm-20, Chromotek) was used for
immunoprecipitation of PES1-mCherry fusion proteins using incubation and
washing buffers as for the lN-peptide-mediated pull-down. RNA was extracted
with TRIzol (Life Technologies)/CHCl3 and precipitated with isopropanol.
Retrieved RNA was reverse transcribed using random hexamer primers
and analysed by qPCR with primers specific for circANRIL (ex7-5) or controls
(CDR1as, circHPRT1).
PulseSILAC. CircANRIL-overexpressing and control cells were attenuated in ‘light’
medium (Silantes) for three passages. After seeding and adhesion for 1 h, cells were
switched to ‘medium’ (SILAC-Lys4-Arg6-Kit, Silantes) and ‘heavy’ medium
(SILAC-Lys8-Arg10-Kit, Silantes) and incubated for 24 h (Fig. 4h). After washing
with PBS, cell were lysed in SDC buffer (1% SDC, 10mM TCEP, 40mM CAA and
100mM Tris (pH 8.5)), boiled for 10min at 95 C, sonicated and diluted 1:1 with
ddH2O before proteolytic digestion. Peptide purification was done59 before mass
spectrometric analyses.
Mass spectrometric data acquisition and data analyses. A unit of 2 mg of
peptides from circANRIL-BoxB and circANRIL control pull-down experiments
(n¼ 4/4) were loaded for 30min gradients separated on a 20 cm column with
75 mm inner diameter in-house packed with 1.9 mm C18 beads (Dr Maisch GmbH).
A unit of 2 mg of peptides from pulseSILAC experiments were loaded for 100min
gradients separated on a 40 cm column with 75 mm inner diameter in-house packed
with 1.9 mm C18 beads (Dr Maisch GmbH). Reverse phase chromatography was
performed at 60 C with an EASY-nLC 1,000 ultra-high pressure system (Thermo
Fisher Scientific) coupled to the Q Exactive Plus mass spectrometer (for RNA
pull-downs) or to the Q Exactive HF mass spectrometer (for pulseSILAC experi-
ments) (Thermo Fisher Scientific) via a nanoelectrospray source (Thermo Fisher
Scientific). Peptides were loaded in buffer A (0.1% (v/v) formic acid) and eluted
with a nonlinear gradient. Operational parameters were real-time monitored by the
SprayQC software60. Raw files were analysed by MaxQuant software (version
1.5.0.0 (RNA pull-downs) or version 1.5.0.38 (pulseSILAC experiments))61, and
peak lists were searched against the Homo sapiens Uniprot FASTA database
(Version 2014/4) and a common contaminants database (247 entries) by the
Andromeda search engine62. Label-free quantification was done using the MaxLFQ
algorithm63 integrated into MaxQuant. Data analysis was performed with the
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Perseus software in the MaxQuant computational platform and in the R statistical
computing environment. Data were imputed by creating a Gaussian distribution of
random numbers with a s.d. of 30% in comparison to the s.d. of measured values,
and one s.d. downshift of the mean to simulate the distribution of low signal values.
miRNA-binding and RNA–protein interaction prediction. Predictions of
miRNA-binding sites were performed using miRanda64 and TargetSpy65
algorithms. miRNA sequences were downloaded from miRBase (Release 21
(ref. 66)). The catRAPID67 and the RNA-Protein Interaction Prediction (RPISeq)
software67,68 were used for predictions of protein–RNA binding. Secondary RNA
structure prediction was performed using the Vienna RNA package69.
Pathway and upstream regulator analyses. Genome-wide expression profiling
revealed 1,864 circANRIL-correlated transcripts in human PBMC (n¼ 2,280;
Po0.001) and 18,09 transcripts with 42- or o0.5-fold expression changes in
circANRIL-overexpressing compared with vector control cells. Using pulseSILAC,
197 proteins with de novo synthesis±10% in circANRIL-overexpressing compared
with control cell lines were identified. Pathway and upstream regulator analyses
were performed using the Ingenuity Pathway Analysis (www.ingenuity.com)
according to standard procedures of the software. Levels of significance were
determined using Fisher’s exact tests implemented in the software. Bonferroni
corrections for the number of tests were applied, and P values with genome-wide
significance are given in Supplementary Tables 5 and 6.
Statistics. Normality of distribution was tested using the Kolmogorov–Smirnov
test implemented in the PRISM statistical software (GraphPad). Comparison of
normally distributed multiple groups was done using analysis of variance and
Tukey was performed as post-test. Comparison of two normally distributed groups
was done using a t-test. Comparison of two non-normally distributed groups was
done using the Mann–Whitney U-test. Mendelian randomization analysis and
associations of haplotypes with gene expression and of circANRIL with athero-
sclerosis were calculated using the R software for statistical computing16,17,70.
Data availability. Gene expression data have been deposited at Gene Expression
Omnibus (http://www.ncbi.nlm.nih.gov/geo/) under the GEO Accession
number GSE65392. The mass spectrometry proteomics data have been deposited
to the ProteomeXchange Consortium via the PRIDE partner repository
(https://www.ebi.ac.uk/pride/archive/) with the data set identifier PXD001769.
Original uncropped scans of DNA agarose gels and of western blots have been
assembled in Supplementary Figs 17 and 18, respectively. All other data are
available on request.
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